ProCE Banner Activity

Contemporary Treatment Strategies for Resectable Melanoma: Is Earlier Immune Checkpoint Blockade Better?

Slideset Download
In this downloadable slideset from a live symposium, experts review key data and provide current recommendations on the use of immune checkpoint inhibitor therapy in the neoadjuvant and upfront settings for patients with advanced melanoma.

Released: March 29, 2019

Expiration: March 27, 2020

No longer available for credit.

Share

Faculty

Rodabe Amaria

Rodabe Amaria, MD

Assistant Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Michael B. Atkins

Michael B. Atkins, MD

Professor of Medicine
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Merck Oncology

Faculty Disclosure

Primary Author

Rodabe Amaria, MD

Assistant Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Michael B. Atkins, MD

Professor of Medicine
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston, Massachusetts